Free Trial
OTCMKTS:EDTXF

Spectral Diagnostics Q1 2026 Earnings Results & Report

Spectral Diagnostics logo
$0.73 -0.01 (-1.35%)
As of 11/13/2026 10:03 AM Eastern

Spectral Diagnostics missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 8, 2026. The company reported EPS of -$0.01 versus the -$0.0072 consensus estimate, while revenue of $641 thousand topped the $542 thousand estimate by $99.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Spectral Diagnostics EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.0072
Beat/Miss
Missed by -$0.0028
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Spectral Diagnostics Revenue Results

Actual Revenue
$641 thousand
Expected Revenue
$542 thousand
Beat/Miss
Beat by +$99.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Spectral Diagnostics Q1 2026 Earnings FAQ

Spectral Diagnostics (OTCMKTS:EDTXF) reported earnings of -$0.01 per share for Q1 2026, missing the consensus estimate of -$0.0072. The report was announced on Friday, May 8, 2026.

Spectral Diagnostics reported revenue of $641 thousand for Q1 2026, against a consensus estimate of $542 thousand.

Spectral Diagnostics Earnings Headlines

Spectral Medical Inc EDTXF
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Diagnostics, now known as Spectral Medical Inc., is a Toronto-based medical technology company focused on the diagnosis and treatment of sepsis and septic shock. Its work centers on detecting endotoxin, a bacterial toxin associated with severe infection and organ dysfunction.

The company’s Endotoxin Activity Assay (EAA) is a blood test designed to help clinicians identify elevated endotoxin activity in critically ill patients. Spectral also develops polymyxin B hemoperfusion, an extracorporeal therapy intended to remove endotoxin from the blood; the therapy has been studied for use in patients with septic shock.

Formerly named Spectral Diagnostics (OTCMKTS:EDTXF), the company has focused on sepsis-related products for decades. Its activities include developing and commercializing the EAA and advancing its endotoxin-removal therapy through clinical research.

View Spectral Diagnostics Profile